Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Sep 2025 value amounting to $70.0 million.

  • Vanda Pharmaceuticals' Cash & Equivalents fell 30.32% to $70.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year decrease of 30.32%. This contributed to the annual value of $102.3 million for FY2024, which is 24.67% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Cash & Equivalents of $70.0 million as of Q3 2025, which was down 13.53% from $81.0 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Cash & Equivalents ranged from a high of $354.2 million in Q1 2023 and a low of $49.4 million during Q3 2022.
  • Its 3-year average for Cash & Equivalents is $137.9 million, with a median of $111.8 million in 2025.
  • In the last 5 years, Vanda Pharmaceuticals' Cash & Equivalents surged by 429.19% in 2023 and then tumbled by 64.66% in 2024.
  • Quarterly analysis of 5 years shows Vanda Pharmaceuticals' Cash & Equivalents stood at $52.1 million in 2021, then surged by 159.32% to $135.0 million in 2022, then climbed by 0.59% to $135.8 million in 2023, then decreased by 24.67% to $102.3 million in 2024, then plummeted by 30.32% to $70.0 million in 2025.
  • Its last three reported values are $70.0 million in Q3 2025, $81.0 million for Q2 2025, and $111.8 million during Q1 2025.